Pneumatosis intestinalis and portal venous gas secondary to Gefitinib therapy for lung adenocarcinoma
© Lee et al; licensee BioMed Central Ltd. 2012
Received: 27 July 2011
Accepted: 10 March 2012
Published: 10 March 2012
Pneumatosis intestinalis (PI), defined as the presence of gas in the bowel wall, and portal venous gas (PVG) are relatively rare radiological findings. Although several chemotherapeutic agents and anti-vascular endothelial growth factor agents are reported to be associated with PI and PVG, an association with anti-epidermal growth factor receptor (EGFR) agents has not been described previously.
The present report describes a case of PI and PVG secondary to treatment with an EGFR tyrosine kinase inhibitor. A 66-year-old woman who had been diagnosed with metastatic lung adenocarcinoma presented with nausea, vomiting and abdominal distension after commencing gefitinib. A computed tomography (CT) scan of the abdomen revealed PI extending from the ascending colon to the rectum, hepatic PVG, and infarction of the liver. Gefitinib therapy was discontinued immediately and the patient was managed conservatively. A follow-up CT scan 2 weeks later revealed that the PI and hepatic PVG had completely resolved.
This is the first report of PI and PVG caused by EGFR tyrosine kinase inhibitor. Although these complications are extremely rare, clinicians should be aware of the risk of PI and PVG in patients undergoing targeted molecular therapy.
Recent advances in our understanding of the biology and molecular mechanisms of cancer have led to the introduction of molecular-targeted agents for the treatment of non-small cell lung cancer (NSCLC). Gefitinib is an orally active selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, an enzyme that regulates the intracellular signaling pathways implicated in the proliferation and survival of cancer cells . Somatic mutations in the region of EGFR that encodes the tyrosine kinase domain of the receptor have been identified in patients with NSCLC and many studies report that NSCLC patients who carry these mutations are highly responsive to gefitinib [2, 3].
In general, targeted molecular therapies such as gefitinib have good toxicity profiles. However, some patients develop specific and severe toxicities, since these molecular targets are also expressed in normal cells. Although gefitinib is generally well tolerated, its most commonly reported side effects are of the gastrointestinal tract (diarrhea, nausea and vomiting) and skin (rash, acne, dry skin and pruritus). Severe gastrointestinal toxicity secondary to gefitinib is uncommon, and only 1% of patients treated with gefitinib develop grade 3 or 4 diarrhea .
The present report describes the development of pneumatosis intestinalis (PI) and portal venous gas (PVG) in a patient with metastatic lung adenocarcinoma who had received gefitinib therapy.
Although gefitinib had led to a partial response, this therapy was now considered to be contraindicated in this patient. Pemetrexed was therefore commenced instead as a third-line therapy. However, the malignant pleural effusion and peritoneal carcinomatosis became exacerbated, and the patient died of bacterial pneumonia with sepsis 18 months after the initial diagnosis.
PI is defined as the presence of gas within the bowel wall and represents a radiological finding rather than a diagnosis . Although it can occur as a primary disease, PI occurs more commonly secondary to other causes which range from benign conditions to fulminant disease [4, 5]. Although the pathogenesis and etiology of PI are not fully understood, its causes can be classified into several conditions: life-threatening bowel necrosis, such as necrotizing enterocolitis and bowel ischemia; raised intra-abdominal pressure due to bowel obstruction, abdominal trauma, ileus, surgery and colonoscopy; increased mucosal permeability associated with steroid therapy, chemotherapy, connective tissue disease and immunosuppressive therapy; respiratory conditions such as chronic bronchitis, emphysema and asthma; trichloroethylene exposure, ingestion of carbohydrate such as lactose or sorbitol; and counter-perfusion super-saturation [4–7]. However, in the present case, no mechanical or bacterial factors, such as bacterial ischemia, bowel obstruction, inflammatory bowel disease, obstructive pulmonary disease or infectious colitis, were identified. In addition, the intraluminal air extended continuously from the ascending colon to the rectum, a pattern which is incompatible with any vascular territory, and an ischemic cause was therefore unlikely. The intra-abdominal metastases of lung adenocarcinoma showed a marked improvement in response to gefitinib therapy. However, the PI developed after the commencement of gefitinib and gradually resolved following its discontinuation. The patient was not taking any other medicines that might have been the cause of PI. We therefore presume that gefitinib played a major role in the development of PI in the present case.
Several chemotherapeutic agents have been reported to be associated with PI, including cyclophosphamide, methotrexate, vincristine, doxorubicin, daunorubicin, cytarabine, fluorouracil, paclitaxel, docetaxel, etoposide, irinotecan and cisplatin [8–10]. Since the intestinal mucosa is highly proliferative, chemotherapy often causes mucosal damage. Chemotherapeutic agents may also interfere with the mucosal integrity of the intestinal tract, resulting in extensive intramural air. However, PI secondary to molecularly-targeted agents is very rare. Recent reports describe the development of PI in patients receiving anti-vascular endothelial growth factor (VEGF) agents such as bevacizumab, sunitinib, and sorafenib [11–13]. VEGF inhibition can damage the microvasculature of the intestinal wall and it is plausible that a secondary insult to the intestine may lead to the development of PI. EGFR tyrosine kinase inhibitors such as gefitinib are associated with more gastrointestinal symptoms than other molecularly-targeted agents, partly as a result of their oral formulation. Although the precise pathophysiology of anti-EGFR agent-related gastrointestinal toxicity remains unclear, EGF is involved in the maintenance of mucosal integrity . EGF deficiency secondary to anti-EGFR agents interferes with the mucosal integrity of the intestinal tract resulting in diarrhea, constipation, nausea and vomiting, and PI.
Furthermore, the patient described herein had a hepatic PVG on CT scan of the abdomen. The finding of PI and PVG during CT scanning usually indicates mesenteric ischemia or infarction [15, 16]. However, both findings are also observed in a range of non-ischemic conditions. Therefore, conservative therapy may be effective, although immediate laparotomy is usually recommended in patients presenting with PVG . In the present case, non-invasive management was indicated since the hepatic PVG was secondary to gefitinib-induced gastrointestinal toxicity rather than to bowel necrosis.
To our knowledge, the present report is the first to identify gefitinib as a cause of PI and PVG, and thus extends the literature concerning gefitinib-induced gastrointestinal toxicity. In conclusion, although PI and PVG are extremely rare complications of targeted molecular therapy, clinicians should be aware of the possibility of PI and PVG in patients receiving anti-EGFR therapies. Further studies are warranted to analyze the biological effects of targeted therapies on normal tissues as well as on cancer cells.
Written informed consent for publication of this case report and associated images could not be obtained from the patient, but the patient's son provided the required consent.
This study was supported by the research grant of the Chungbuk National University in 2011. Written consent was obtained from the patient's son for publication of the study.
- Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002, 62: 5749-5754.PubMed
- Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009, 361: 947-957. 10.1056/NEJMoa0810699.View ArticlePubMed
- Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T, North-East Japan Study Group: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010, 362: 2380-2388. 10.1056/NEJMoa0909530.View ArticlePubMed
- Heng Y, Schuffler MD, Haggitt RC, Rohrmann CA: Pneumatosis intestinalis: a review. Am J Gastroenterol. 1995, 90: 1747-1758.PubMed
- Ho LM, Paulson EK, Thompson WM: Pneumatosis intestinalis in the adult: benign to life-threatening causes. AJR Am J Roentgenol. 2007, 188: 1604-1613. 10.2214/AJR.06.1309.View ArticlePubMed
- Tsujimoto T, Shioyama E, Moriya K, Kawaratani H, Shirai Y, Toyohara M, Mitoro A, Yamao J, Fujii H, Fukui H: Pneumatosis cystoides intestinalis following alpha-glucosidase inhibitor treatment: a case report and review of the literature. World J Gastroenterol. 2008, 14: 6087-6092. 10.3748/wjg.14.6087.PubMed CentralView ArticlePubMed
- Florin TH, Hills BA: Does counterperfusion supersaturation cause gas cysts in pneumatosis cystoides coli, and can breathing heliox reduce them?. Lancet. 1995, 345: 1220-1222. 10.1016/S0140-6736(95)91996-1.View ArticlePubMed
- Shih IL, Lu YS, Wang HP, Liu KL: Pneumatosis coli after etoposide chemotherapy for breast cancer. J Clin Oncol. 2007, 25: 1623-1625. 10.1200/JCO.2006.10.5742.View ArticlePubMed
- Kung D, Ruan DT, Chan RK, Ericsson ML, Saund MS: Pneumatosis intestinalis and portal venous gas without bowel ischemia in a patient treated with irinotecan and cisplatin. Dig Dis Sci. 2008, 53: 217-249. 10.1007/s10620-007-9846-9.View ArticlePubMed
- Mimatsu K, Oida T, Kawasaki A, Kano H, Kuboi Y, Aramaki O, Amano S: Pneumatosis cystoides intestinalis after fluorouracil chemotherapy for rectal cancer. World J Gastroenterol. 2008, 14: 3273-3275. 10.3748/wjg.14.3273.PubMed CentralView ArticlePubMed
- Asmis TR, Chung KY, Teitcher JB, Kelsen DP, Shah MA: Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity. Invest New Drugs. 2008, 26: 95-96. 10.1007/s10637-007-9094-z.View ArticlePubMed
- Flaig TW, Kim FJ, La Rosa FG, Breaker K, Schoen J, Russ PD: Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma. Invest New Drugs. 2009, 27: 83-87. 10.1007/s10637-008-9146-z.View ArticlePubMed
- Coriat R, Ropert S, Mir O, Billemont B, Chaussade S, Massault PP, Blanchet B, Vignaux O, Goldwasser F: Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib. Invest New Drugs. 2010,
- Matsuura M, Okazaki K, Nishio A, Nakase H, Tamaki H, Uchida K, Nishi T, Asada M, Kawasaki K, Fukui T, Yoshizawa H, Ohashi S, Inoue S, Kawanami C, Hiai H, Tabata Y, Chiba T: Therapeutic effects of rectal administration of basic fibroblast growth factor on experimental murine colitis. Gastroenterology. 2005, 128: 975-986. 10.1053/j.gastro.2005.01.006.View ArticlePubMed
- Schulze CG, Blum U, Haag K: Hepatic portal venous gas. Imaging modalities and clinical significance. Acta Radiol. 1995, 36: 377-380.PubMed
- Kernagis LY, Levine MS, Jacobs JE: Pneumatosis intestinalis in patients with ischemia: correlation of CT findings with viability of the bowel. AJR Am J Roentgenol. 2003, 180: 733-736.View ArticlePubMed
- Wayne E, Ough M, Wu A, Liao J, Andresen KJ, Kuehn D, Wilkinson N: Management algorithm for pneumatosis intestinalis and portal venous gas: treatment and outcome of 88 consecutive cases. J Gastrointest Surg. 2010, 14: 437-448. 10.1007/s11605-009-1143-9.View ArticlePubMed
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/12/87/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.